Neoadjuvant RCT Versus CT for Patients With Locally Advanced, Potentially Resectable Adenocarcinoma of the GEJ

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE3

Total Enrollment

342 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-06-03

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a multicenter, prospective, randomized, stratified, controlled, open-label study comparing neoadjuvant radiochemotherapy with FLOT versus FLOT chemotherapy alone für patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction (GEJ)

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Perioperative Chemotherapy Compared To Neoadjuvant Chemoradiation in Patients With Adenocarcinoma of the Esophagus

NCT02509286

Esophageal Adenocarcinoma (UICC TNM7) Adenocarcinoma of the Esophagogastric Junction

ACTIVE_NOT_RECRUITING PHASE3

Evaluation for the Individualization of Therapy in Adenocarcinomas of the Gastroesophageal Junction

NCT02287129

Adenocarcinoma of the Esophagogastric Junction

COMPLETED PHASE2

An Open-label, Single-center, Phase 1/ 2 Study of Chemoradiotherapy and AT-101 in Patients With Locally Advanced Esophageal or Gastroesophageal Junction Cancer

NCT00561197

Locally Advanced Esophageal or GE Junction Cancer

TERMINATED PHASE1/PHASE2

NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study (Neo-AEGIS)

NCT01726452

Adenocarcinoma of the Oesophagus Adenocarcinoma of the Oesophago-gastric Junction Oesophageal Tumours +2 more

COMPLETED PHASE3

Dose Escalation of Neoadjuvant Proton Beam Radiotherapy With Concurrent Chemotherapy in Locally Advanced Esophageal Cancer

NCT02213497

Esophageal Cancer

ACTIVE_NOT_RECRUITING PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The RACE trial seeks to demonstrate superiority of preoperative FLOT induction chemotherapy followed by preoperative radiochemotherapy and postoperative FLOT chemotherapy over perioperative FLOT chemotherapy without radiotherapy in patients with adenocarcinoma of the gastroesophageal junction undergoing adequate oncological surgery.

Eligible patients will be randomly allocated to one of two treatment groups, i.e. preoperative chemotherapy (Arm A) or preoperative chemotherapy with subsequent preoperative radiochemotherapy (arm B), both followed by resection and postoperative completion of chemotherapy. Randomization will occur in a 1:1 ratio with stratification by primary tumor site (Siewert I vs. Siewert II/III).

Arm A:

Patients randomized to Arm A (control arm) will be treated with four preoperative cycles of FLOT. Cycles will be repeated every two weeks. The preoperative chemotherapy duration in Arm A is eight weeks. Surgical resection will follow 4-6 weeks after day 1 of the last cycle of neoadjuvant therapy. Postoperative chemotherapy will start 6-12 weeks after surgery and consists of another four cycles of FLOT every two weeks. The total treatment period is 25-32 weeks.

Arm B:

Patients randomized in Arm B (experimental arm) will be treated with two cycles of FLOT every two weeks. Radiochemotherapy will start three weeks after day 1 of the second cycle and consists of oxaliplatin and infusional 5-fluorouracil plus concurrent radiotherapy given to a dose of 45 Gy (25 daily fractions with 1.8 Gy) over five weeks. The preoperative treatment duration is 10 weeks. Surgical resection will follow 4-6 weeks after last treatment with chemotherapy / radiation. Postoperative chemotherapy will start 6-12 weeks after surgery and consists of four cycles of FLOT every two weeks. The total treatment period is 26-33 weeks.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gastroesophageal Junction Adenocarcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm A (control arm)

Patients randomized in control arm A will receive four cycles of neoadjuvant chemotherapy with FLOT every two weeks (5-FU 2600 mg/m² d1, folinc acid 200 mg/m² d1, oxaliplatin 85 mg/m² d1, docetaxel 50 mg/m² d1) followed by surgical resection 4-6 weeks after day 1 of the last cycle of neoadjuvant therapy. 6-12 weeks after surgery adjuvant chemotherapy starts with 4 cycles of FLOT (total treatment period 25-32 weeks).

Group Type ACTIVE_COMPARATOR

5-Fluorouracil

Intervention Type DRUG

Day 1 q2w: 2600 mg/m² IV over 24 hours

Calcium folinate

Intervention Type DRUG

Day 1 q2w: 200 mg/m² IV over 2 hours

Oxaliplatin

Intervention Type DRUG

Day 1 q2w: 85 mg/m² IV over 2 hours

Docetaxel

Intervention Type DRUG

Day 1 q2w: 50 mg/m² IV over 2 hours

Arm B (experimental arm)

Patients randomized in experimental arm B will receive two cycles of neoadjuvant induction chemotherapy with FLOT (5-FU 2600 mg/m² d1, folinic acid 200 mg/m² d1, oxaliplatin 85 mg/m² d1, docetaxel 50 mg/m² d1) every two weeks (4 weeks of therapy) followed by radiochemo-therapy beginning at day 21 after day one of the last cycle of chemotherapy. Radiochemotherapy consists of oxaliplatin 45 mg/m² weekly (d1, 8, 15, 22, 29) and continuous infusional 5-FU 225 mg/m² plus concurrent radiotherapy given in 5/week fractions with 1.8 Gy to a dose of 45 Gy over 5 weeks. Resection is performed 4-6 weeks after last treatment with chemotherapy / radiation. Adjuvant treatment starts 6-12 weeks after surgery and consists of 4 cycles of FLOT (total treatment period of 26 - 33 weeks).

Group Type EXPERIMENTAL

5-Fluorouracil

Intervention Type DRUG

Day 1 q2w: 2600 mg/m² IV over 24 hours

Calcium folinate

Intervention Type DRUG

Day 1 q2w: 200 mg/m² IV over 2 hours

Oxaliplatin

Intervention Type DRUG

Day 1 q2w: 85 mg/m² IV over 2 hours

Docetaxel

Intervention Type DRUG

Day 1 q2w: 50 mg/m² IV over 2 hours

Radiation

Intervention Type RADIATION

25 fractions (5 each week over 5 weeks) each 1,8 Gy to a total of 45 Gy

Oxaliplatin during radiotherapy

Intervention Type DRUG

Day 1, 8, 15, 22, 29: 45 mg/m² IV over 2 hours

5-Fluorouracil during radiotherapy

Intervention Type DRUG

day 1 - 33: 225 mg/m²/day IV continuously

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

5-Fluorouracil

Day 1 q2w: 2600 mg/m² IV over 24 hours

Intervention Type DRUG

Calcium folinate

Day 1 q2w: 200 mg/m² IV over 2 hours

Intervention Type DRUG

Oxaliplatin

Day 1 q2w: 85 mg/m² IV over 2 hours

Intervention Type DRUG

Docetaxel

Day 1 q2w: 50 mg/m² IV over 2 hours

Intervention Type DRUG

Radiation

25 fractions (5 each week over 5 weeks) each 1,8 Gy to a total of 45 Gy

Intervention Type RADIATION

Oxaliplatin during radiotherapy

Day 1, 8, 15, 22, 29: 45 mg/m² IV over 2 hours

Intervention Type DRUG

5-Fluorouracil during radiotherapy

day 1 - 33: 225 mg/m²/day IV continuously

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Folinic Acid

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Histologically proven, locally advanced and potentially resectable adenocarcinoma of the gastroesophageal junction (GEJ) (Siewert I- III) that is: cT3-4, any N, M0 or cT2 N+, M0 according to AJCC 8th edition
2. Patients\* must be candidates for potential curative resection as determined by the treating surgeon
3. ECOG performance status 0-1
4. Age 18 years or above
5. Adequate hematologic function with absolute neutrophil count (ANC) ≥ 1.5 x 10\^9/l, platelets ≥ 100 x 10\^9/l and hemoglobin ≥ 9.0 mg/dl
6. INR \<1.5 and aPTT\<1.5 x upper limit of normal (ULN) within 7 days prior to randomization
7. Adequate liver function as measured by serum transaminases (ASAT, ALAT) ≤ 2.5 x ULN and total bilirubin ≤ 1.5 x ULN
8. Adequate renal function with serum creatinine ≤ 1.5 x ULN
9. QTc interval (Bazett\*) ≤ 440 ms
10. Written informed consent obtained before randomization
11. Negative pregnancy test for women of childbearing potential within 7 days of commencing study treatment. Males and females of reproductive potential must agree to practice highly effective\*\*\* contraceptive measures during the study and for 6 months after the end of study treatment. Male patients must also agree to refrain from father a child during treatment and up to 6 months afterwards and additionally to use a condom during treatment period. Their female partner of childbearing potential must also agree to use an adequate contraceptive measure.

* \*There are no data that indicate special gender distribution. Therefore, patients will be enrolled in the study gender-independently.
* \*\* formula for QTc interval calculation (Bazett): QTc= ((QT) ̅" (ms)" )/√(RR (sec))= ((QT) ̅" (ms)" )/√(60/(Frequence (1/min)))
* \*\*\* highly effective (i.e. failure rate of \<1% per year when used consistently and correctly) methods: intravaginal and transdermal combined (estrogen and progestogen containing) hormonal contraception; injectable and implantable progestogen-only hormonal contraception; intrauterine device (IUD); intrauterine hormone-releasing system (IUS); bilateral tubal occlusion; vasectomised partner; sexual abstinence (complete abstinence is defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments).

Exclusion Criteria

1. Evidence of metastatic disease (exclusion of distant metastasis by CT of thorax and abdomen, bone scan or MRI \[if osseous lesions are suspected due to clinical signs\])
2. Past or current history (within the last 5 years prior to treatment start) of other malignancies. Patients with curatively treated basal and squamous cell carcinoma of the skin or in situ carcinoma of the cervix are eligible
3. Evidence of peripheral sensory neuropathy \> grade 1 according to CTCAE version 4.03
4. Patients with other significant underlying medical conditions that may be aggravated by the study treatment or are not controlled
5. Pregnant or lactating females
6. Patients medically unfit for chemotherapy and radiotherapy
7. Patients receiving any immunotherapy, cytotoxic chemotherapy or radiotherapy other than defined by the protocol. The participation in another clinical trial with the use of investigational agents, chemotherapy or radiotherapy during the trial is not permitted
8. Known hypersensitivity against 5-FU, folinc acid, oxaliplatin or docetaxel
9. Other known contraindications against 5-FU, folinic acid, oxaliplatin, or docetaxel
10. Clinically significant active coronary heart disease, cardiomyopathy or congestive heart failure, NYHA III-IV
11. Clinically significant valvular defect
12. Other severe internal disease or acute infection
13. Peripheral polyneuropathy \> NCI Grade II according to CTCAE version 4.03
14. Chronic inflammatory bowel disease

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No